November 18, 2026
Health news, explained with evidence
LIVE

Urine-Based Biomarkers Show Potential for Monitoring Bladder Cancer Progression

🧠 AI Analysis 2 min read 👁 0

Researchers have identified four urinary protein markers that may assist in the diagnosis and treatment monitoring of advanced bladder cancer. These findings suggest a non-invasive approach to tracking tumor response to chemotherapy or radiotherapy.

🧠AI Analysis

Key points

  • Four secreted proteins were identified as potential biomarkers for bladder cancer.
  • The combined protein panel showed high accuracy in distinguishing patients with stage T1 or higher disease.
  • Urinary COL1A1 levels showed a 92.3% correlation with CT-based treatment response.

A study conducted by researchers at the Dongnam Institute of Radiological & Medical Sciences has identified a panel of four urinary proteins that could serve as potential biomarkers for high-stage bladder cancer. By analyzing transcriptomic data, the team isolated specific proteins—COL1A1, MFAP5, DPP4, and ECM1—that appear to be linked to treatment resistance in bladder cancer cells. When tested in a cohort of 57 patients, the combined panel of these four markers demonstrated high diagnostic accuracy, particularly for tumors at stage T1 or higher.

The study also examined 13 patients undergoing systemic chemotherapy or radiotherapy to determine if these markers could track treatment efficacy. Findings indicated that changes in the levels of COL1A1, MFAP5, and ECM1 often aligned with results observed in CT scans, with COL1A1 showing a 92.3% concordance rate with imaging outcomes. These results suggest that urine-based liquid biopsies might eventually offer a less invasive way to monitor disease status during the course of therapy.

What to know: While these results are promising, this was an exploratory study with a limited sample size. Further research is necessary to determine if these markers provide additional clinical value beyond standard imaging techniques and how they perform in broader surveillance settings. Patients should consult with their healthcare providers regarding appropriate diagnostic and monitoring procedures for bladder cancer.

Source Nature Health Sciences — nature.com/articles/s41598-026-78109-w ↗

Contact the newsroom

Got a tip, a proposal or a partnership question? Write to us and we will reply shortly.